Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.
Martin J. van den Bent(Erasmus MC Cancer Institute), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Pim J. French(Erasmus MC Cancer Institute), Iris de Heer(Erasmus MC Cancer Institute), Filip De Vos(University Medical Center Utrecht), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Tina Verschuere(KU Leuven), Marion Smits(Erasmus MC), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Martin Taphoorn(Leiden University Medical Center), Johan M. Kros(Erasmus MC), Wolfgang Wick(German Cancer Research Center), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Joanne Lewis(Freeman Hospital), Martin Klein(Amsterdam University Medical Centers), Paul M. Clément(Universitair Ziekenhuis Leuven), Vassilis Golfinopoulos(Champalimaud Foundation)
Cited by 10
Related Papers
Recommended implementation of arterial spin‐labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia
|Magnetic Resonance in Medicine|2014|2.2k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k